RO7851624 for Multiple Myeloma That Has Returned or Stopped Responding to Treatment
Tests RO7851624 in adults with multiple myeloma who have few treatment options left.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Key facts
- Where
- Parkville, AustraliaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. They must already have had three main types of myeloma drugs and have few standard options left.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Relapsed or refractory multiple myeloma, diagnosed by IMWG criteria, with measurable disease; already treated with proteasome inhibitors, immunomodulators and anti-CD38 antibodies
- Earlier treatment
- Must have had proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 monoclonal antibodies, with few standard treatment options left
Main reasons for not taking part
- Other anti-cancer treatment too recently before the first dose
- Autologous stem cell transplant too recently before the first dose
- Earlier allogeneic stem cell transplant
- Earlier solid organ transplant
Read by machine on 10 November 2026.
Where in Australia
- Peter MacCallum Cancer CenterParkville, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Genentech, Inc.
- Trial code
- NCT07558915
- Record updated
- 9 November 2026
- Original description
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.Read full original descriptionShow less
An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.
Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; Life expectancy of at least 12 weeks; Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria; Measurable disease.
Exclusion: Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment; Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment; Prior allogeneic SCT; Prior solid organ transplantation.